Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.
Journal: The New England journal of medicine
Published: April 08, 2024
Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI.
Journal: Journal of the American College of Cardiology
Published: March 12, 2024
CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial.
Journal: Journal of cardiovascular pharmacology and therapeutics
Published: October 25, 2022
Early and late recurrent cardiovascular events among high-risk patients with an acute coronary syndrome: Meta-analysis of phase III studies and implications on trial design.
Journal: Clinical cardiology
Published: September 01, 2021
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.
Journal: American heart journal
Published: November 21, 2019
Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A-I [Human]) to Enhance Cholesterol Efflux Capacity.
Journal: Journal of clinical pharmacology
Published: September 25, 2018
Developing New Treatments for Heart Failure: Focus on the Heart.
Journal: Circulation. Heart failure
Published: October 02, 2015
Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction.
Journal: European journal of heart failure
Published: March 09, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026